.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,855,496

« Back to Dashboard

Details for Patent: 6,855,496

Title: Truncation SELEX method
Abstract:This invention is directed to a method for identifying nucleic acid ligands by the SELEX method wherein the participation of fixed sequences is eliminated or minimized.
Inventor(s): Pagratis; Nikos (Boulder, CO), Gold; Larry (Boulder, CO), Shtatland; Timur (Boulder, CO), Javornik; Brenda (Boulder, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jul 17, 2001
Application Number:09/907,111
Claims:1. A method of identifying a single stranded RNA ligand of a target molecule from a candidate mixture of single-stranded RNA molecules each comprising a region of randomized sequence, said method comprising: a) contacting said candidate mixture with said target molecule; b) partitioning the RNA molecules having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; c) adding a first tail sequence to said RNA molecules partitioned in step b) using terminal transferase; d) reverse transcribing said tailed RNA molecules to cDNA using a primer complementary to said first tail sequence; e) adding a second tail sequence to said cDNA molecule using terminal transferase, wherein said first and said second tail sequences have different sequences; f) amplifying said tailed cDNA molecules of e) using said primer of step d) and a primer comprising sequence complementary to said second tail sequence and further comprising an RNA polymerase promoter sequence, whereby double stranded DNA template is produced; g) transcribing said double stranded DNA template off) to yield single-stranded RNA molecules; and h) removing said tail sequences from said single-stranded RNA molecules of g) whereby a single-stranded RNA ligand of said target molecule is identified.

2. The method of claim 1 further comprising repeating steps a) through h).

3. A method of identifying a single stranded RNA ligand of a target molecule from a candidate mixture of single-stranded RNA molecules each comprising a region of randomized sequence, said method comprising: a) contacting said candidate mixture with said target molecule; b) partitioning the RNA molecules having an increased affinity to the target molecule relative to the candidate mixture from the remainder of the candidate mixture; c) attaching a first oligonucleotide to the 3' end of said RNA molecules partitioned in step b); d) reverse transcribing said RNA molecules of c) to form cDNA using a primer complementary to said first oligonucleotide; e) attaching a double-stranded deoxy oligonucleotide to said cDNA, said double-stranded deoxy oligonucleotide comprising a RNA polymerase promoter; f) amplifying the cDNA of step e) to form a double-stranded DNA template; g) transcribing said amplified double-stranded DNA template to yield single-stranded RNA molecules; and h) removing said first oligonucleotide sequence from said single-stranded RNA molecules of g) whereby a single-stranded RNA ligand of said target molecule is identified.

4. The method of claim 3 further comprising repeating steps a) through h).

5. A method for identifying nucleic acid ligands of a target molecule from a candidate mixture comprised of single stranded nucleic acids each having a region of randomized sequence, said method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; c) amplifying the increased affinity nucleic acids, in vitro, to yield a ligand-enriched mixture of nucleic acids; d) optionally repeating steps a)-c) using the ligand enriched mixture of each successive repeat as many times as required to yield a desired level of ligand enrichment; e) randomly fragmenting the amplified increased affinity nucleic acids; f) inserting fragments of a predetermined length into a circular vector; and g) amplifying the inserted fragments using primers complementary to sequences in said circular vector that flank said inserted fragments, whereby nucleic acid ligands of said target having said predetermined length are identified.

6. The method of claim 5 wherein said candidate mixture is comprised of RNA.

7. The method of claim 5 wherein said candidate mixture is comprised of DNA.

8. The method of claim 6 wherein said ribonucleic acids are modified ribonucleic acids.

9. The method of claim 7 wherein said deoxyribonucleic acids are modified deoxyribonucleic acids.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc